Jardiance Cost in Colorado 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Does Jardiance Actually Cost in Colorado in 2026?

The cash-pay price for a 30-tablet supply of Jardiance at Colorado retail pharmacies sits at approximately $680 per month in 2026, matching the Boehringer Ingelheim and Eli Lilly manufacturer list price. That figure applies whether you are buying at a Denver Walgreens or a rural independent pharmacy in Pueblo. No FDA-approved generic empagliflozin existed as of early 2026, so there is no lower-cost generic option at standard retail chains [1].

Because the molecule still holds market exclusivity, price variation between Colorado pharmacies is modest. GoodRx and similar discount platforms have produced retail quotes in the $580 to $680 range for Colorado zip codes, but those quotes require presenting a coupon card and paying entirely out of pocket, which disqualifies the purchase from counting toward most insurance deductibles. Patients who are uninsured or in a high-deductible plan face the full weight of that monthly cost without any subsidy.

The FDA label for Jardiance covers three distinct clinical indications: type 2 diabetes mellitus, heart failure (including both reduced and preserved ejection fraction after the EMPEROR-Preserved trial), and chronic kidney disease [2]. Each indication is supported by large outcome trials, but Colorado Medicaid's coverage decision does not mirror that clinical breadth, a gap addressed in the Medicaid section below.

Empagliflozin 10 mg and 25 mg tablets carry the same list price. Clinicians generally start patients on 10 mg once daily and escalate to 25 mg only for additional glycemic lowering in type 2 diabetes; both doses produce similar cardiovascular and renal benefits [3].

How Colorado Medicaid Covers Jardiance

Colorado Medicaid (Health First Colorado) covers Jardiance for type 2 diabetes under its preferred drug list, but that coverage does not extend to patients whose primary diagnosis is heart failure or chronic kidney disease without a concurrent type 2 diabetes diagnosis. This distinction matters clinically: EMPA-REG OUTCOME (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death in patients with established atherosclerotic cardiovascular disease taking empagliflozin 10 mg or 25 mg versus placebo (hazard ratio 0.62 to 95% CI 0.49 to 0.77, P<0.001) [4]. Many of those patients had heart failure as a comorbidity, yet Colorado Medicaid's current formulary position would not cover the drug for a patient with heart failure who does not also carry a type 2 diabetes diagnosis.

Prior authorization is required for most Medicaid recipients in Colorado, even within the approved type 2 diabetes indication. The Health First Colorado prior authorization form asks prescribers to document an inadequate response to or intolerance of metformin, which remains the preferred first-line agent under the American Diabetes Association's 2024 Standards of Care [5]. If metformin is contraindicated, such as in stage 4 or 5 chronic kidney disease where eGFR falls below 30 mL/min/1.73 m², that clinical detail should appear explicitly in the PA submission.

Patients enrolled in a Colorado Medicaid managed care organization (MCO) such as Bright Health or Colorado Access may encounter slightly different formulary tiers. Calling the MCO's pharmacy benefits line before prescribing saves the patient weeks of administrative back-and-forth [6].

For the heart failure population specifically, the American Heart Association's 2022 Heart Failure Guidelines classify SGLT2 inhibitors as a Class I recommendation (Level of Evidence A) in patients with HFrEF to reduce cardiovascular death and hospitalization [7]. Colorado Medicaid's coverage gap therefore puts some of the patients with the strongest evidence-based indication in the position of paying out of pocket.

Private Insurance Coverage for Jardiance in Colorado

Most large commercial plans operating in Colorado, including Anthem Blue Cross Blue Shield Colorado, Cigna, Aetna, and Kaiser Permanente of Colorado, include Jardiance on formulary, typically at tier 2 or tier 3. Tier placement directly controls what a patient pays at the pharmacy counter.

A tier 2 placement often results in a $50 to $100 co-pay per month with standard commercial coverage, while tier 3 can push that figure to $150 to $250 or more before the deductible is met [8]. During the deductible phase, even insured patients may pay the full negotiated rate, which sits below the $680 list price at most PBM-contracted pharmacies but can still exceed $400 per fill.

The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 annually starting in 2025. Colorado residents enrolled in Medicare Part D who have reached that cap owe $0 for the remainder of the benefit year, regardless of how expensive their prescriptions are. For a patient taking Jardiance at $680 per month, the cap is typically reached within the first three to four months of the year [9].

Colorado's Division of Insurance regulates all state-regulated plans and maintains a consumer assistance line (1-800-930-3745) that can walk patients through formulary comparison across plans during open enrollment. Choosing a plan that places empagliflozin at tier 2 rather than tier 3 can save more than $1,200 annually for a patient who stays on the drug year-round [10].

The Boehringer Ingelheim and Lilly Savings Card

Boehringer Ingelheim and Eli Lilly co-market Jardiance and jointly offer a manufacturer savings card for commercially insured patients in Colorado. Under the current program terms, eligible patients with commercial insurance may pay as little as $10 per month for a 30-day supply, with a maximum savings of $150 per fill.

The savings card is not usable by patients enrolled in Medicare, Medicaid, or any other federally funded program. Using the card while enrolled in a federal program violates program terms and, in some interpretations, anti-kickback statute provisions [11]. Patients need to verify their eligibility before presenting the card at the pharmacy.

Enrollment is handled online at the Jardiance savings card portal (jardiance.com) or by calling 1-800-545-6962. There is no income threshold for the commercial savings card; the only requirement is active commercial insurance coverage for Jardiance. The card can be combined with co-pay assistance from some employer benefit programs, though stacking rules vary by plan.

For uninsured patients, Boehringer Ingelheim maintains a patient assistance program (PAP) that may provide Jardiance at no cost to qualifying individuals. Income thresholds for the PAP are typically set at or below 400% of the federal poverty level, which in 2026 translates to roughly $58,320 for a single-person household [12].

Is Compounded Empagliflozin Legal in Colorado?

Compounded empagliflozin is legal in Colorado when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding, and Colorado state pharmacy law does not impose additional restrictions that would prohibit compounding empagliflozin for an individual patient [13].

The legal threshold is meaningful. A 503A pharmacy may compound empagliflozin only when a licensed prescriber determines that a commercially available product does not meet the specific medical need of the patient. Common documented rationales include a documented allergy to an inactive excipient in the branded tablet, a required dose that differs from commercially available strengths, or a swallowing disorder that necessitates a liquid formulation [14].

The FDA does not currently place empagliflozin on any category of "essentially a copy" restriction for compounding, so patient-specific compounding remains permissible under federal oversight as of early 2026. However, the regulatory environment for SGLT2 inhibitor compounding has been under agency scrutiny since the widespread interest in GLP-1 compounding began in 2023. Prescribers should document the patient-specific rationale thoroughly in the chart [15].

Pricing for compounded empagliflozin varies by pharmacy and formulation. Some Colorado-based 503A pharmacies have quoted cash prices in the range of $80 to $180 per month for a 10 mg daily dose, representing a 74% to 88% reduction from the branded list price. Those quotes are not standardized, and quality control standards at 503A pharmacies can vary. Patients should verify that the compounding pharmacy holds current licensure with the Colorado State Board of Pharmacy and carries USP 795 and USP 800 compliance certification [16].

Key point: Compounded empagliflozin is not FDA-approved and has not undergone the same bioavailability and bioequivalence testing as Jardiance. The clinical outcomes data, including the 14% reduction in composite cardiovascular and renal events reported in the EMPA-KIDNEY trial (N=6,609), were generated using the branded, FDA-approved formulation [17].

Clinical Evidence That Makes Empagliflozin Worth the Cost

Empagliflozin's price tag is high, but the outcomes data behind the molecule spans three separate indication-defining trials with hard endpoints.

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease and found that empagliflozin reduced the rate of the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority, P=0.04 for superiority) [4]. The cardiovascular death reduction alone was 38%.

EMPEROR-Reduced (N=3,730) showed that empagliflozin 10 mg once daily reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF [18]. EMPEROR-Preserved (N=5,988) extended that finding to patients with HFpEF, with a 21% relative risk reduction in the same composite endpoint (hazard ratio 0.79 to 95% CI 0.69 to 0.90, P<0.001) [19].

EMPA-KIDNEY (N=6,609) enrolled adults with chronic kidney disease across a wide range of eGFR values and demonstrated a 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) [17].

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established or high risk for cardiovascular disease, heart failure, or chronic kidney disease, an SGLT2 inhibitor with proven benefit is recommended as part of the glucose-lowering regimen independent of A1C level" [5]. That language means empagliflozin may be appropriate even when a patient's blood sugar is well controlled, because the cardiovascular and renal benefits operate through mechanisms independent of glycemic action [20].

How Telehealth Prescribing Works for Jardiance in Colorado

Jardiance can be prescribed via telehealth in Colorado. The state does not require an in-person visit before a prescriber issues a prescription for empagliflozin. Colorado follows the Ryan Haight Act framework for controlled substances, but empagliflozin is not a controlled substance, so no additional federal telehealth prescribing restrictions apply [21].

A Colorado-licensed prescriber conducting a synchronous audio-visual visit can evaluate a patient, order baseline labs (commonly a comprehensive metabolic panel, urinalysis, and eGFR), and issue a Jardiance or compounded empagliflozin prescription. The prescription can be sent to any Colorado-licensed pharmacy, including mail-order pharmacies, which may offer lower dispensing fees.

HealthRX clinicians conducting telehealth visits in Colorado document an eGFR at baseline before initiating empagliflozin. The FDA label advises against initiating in patients with an eGFR below 20 mL/min/1.73 m² for the CKD indication and notes reduced glucose-lowering efficacy below eGFR 45 mL/min/1.73 m² [2]. Those thresholds guide dosing decisions made remotely with the same standard of care as an in-person clinic visit.

What's the Cheapest Way to Get Jardiance in Colorado?

The lowest realistic out-of-pocket paths, ranked from least to most expensive for a commercially insured Colorado patient, are:

Manufacturer savings card with commercial insurance. Eligible patients pay as little as $10 per month. This is the lowest cost option for those who qualify and carry commercial coverage [11].

Compounded empagliflozin via 503A pharmacy. For patients who are uninsured, underinsured, or whose insurance does not cover Jardiance, compounded empagliflozin from a licensed Colorado 503A pharmacy may cost $80 to $180 per month with a documented clinical rationale [14].

Patient assistance program. Uninsured patients at or below roughly 400% of the federal poverty level may receive Jardiance at no cost through Boehringer Ingelheim's PAP [12].

Medicare Part D after $2,000 cap. Colorado residents on Medicare who hit the $2,000 annual out-of-pocket cap owe $0 for the rest of the benefit year [9].

GoodRx or cash-pay discount card. Uninsured patients who do not qualify for the PAP and do not have a clinical rationale for compounding can use a GoodRx coupon for prices in the $580 to $650 range at major Colorado chains, still far below list but by far the most expensive of the available options [8].

Safety Considerations Colorado Patients and Prescribers Should Know

Empagliflozin carries a boxed-level FDA warning for the risk of Fournier's gangrene (necrotizing fasciitis of the perineum), a rare but severe adverse event reported across the SGLT2 inhibitor class. Patients should be counseled to report any perineal pain, swelling, or tenderness immediately [2].

Diabetic ketoacidosis (DKA) can occur even at normal blood glucose levels with SGLT2 inhibitors, a pattern called euglycemic DKA. The risk is higher in patients who are fasting, volume-depleted, or who have significantly reduced insulin doses around surgery. Colorado's high-altitude environment does not independently increase DKA risk, but physical activity at altitude can accelerate fluid losses, requiring extra hydration counseling [22].

Genital mycotic infections occur in roughly 6% to 7% of women and 3% of men taking empagliflozin in clinical trials, compared with 1% to 2% in placebo groups [3]. These infections are generally mild and respond to standard antifungal therapy, but patients deserve proactive counseling before the first prescription is filled.

Urinary tract infections occur at rates similar to placebo in most SGLT2 inhibitor trials, but urinary symptoms should not be dismissed, particularly in older female patients who may have subclinical urinary tract abnormalities [23].

Hold empagliflozin at least 3 to 4 days before any planned surgery or major procedure requiring prolonged fasting. The Endocrine Society's perioperative guidance recommends this pause to reduce euglycemic DKA risk [24]. Reinitiate only after the patient is eating normally and is hemodynamically stable.

Drug Interactions and Lab Monitoring in Colorado Practice

Insulin and sulfonylureas used concurrently with empagliflozin increase hypoglycemia risk. When adding empagliflozin to an existing regimen that includes either agent, reducing the insulin or sulfonylurea dose by 20% to 50% is a reasonable starting point, guided by the patient's current glycemic control [5].

Diuretics, particularly loop diuretics such as furosemide, can compound the volume-depletion effect of empagliflozin's osmotic diuresis. Blood pressure and serum creatinine should be reassessed within four weeks of initiating empagliflozin in any patient on a loop diuretic [7].

Baseline labs before starting empagliflozin should include serum creatinine or eGFR, serum potassium, a urinalysis, and, in patients with diabetes, an HbA1c. Follow-up eGFR at three months helps identify patients with a significant early decline that warrants dose review [17].